1
|
Martínez M, Mariani ML, García C, Ceñal JP, Penissi AB. A one-pot and eco-friendly synthesis of novel β-substituted-α-halomethyl acrylates and the bioactivity of these compounds in an in vitro model of mast cell degranulation induced by pro-inflammatory stimuli. Biomed Pharmacother 2024; 170:116009. [PMID: 38134632 DOI: 10.1016/j.biopha.2023.116009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 12/03/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023] Open
Abstract
The goal of the present work was to develop novel β-substituted-α-halomethyl acrylates from a methodology in an aqueous phase and to evaluate their bioactivity as potential inhibitors of mast cell activation. Eleven β-substituted-α-halomethyl acrylates were synthesized through a modified Horner-Wadsworth-Emmons reaction. Compound 48/80 and the calcium ionophore A23187 stimulated the release of β-hexosaminidase from mast cells. The effect induced by compound 48/80 was inhibited by compound 5 (320 µM) and compound 9 (160 and 320 µM) without causing cytotoxic effects. The effect induced by A23187 was inhibited by compound 5 (40, 80, 160, and 320 µM) without affecting cell viability. The inhibitory effects exhibited by compounds 5 and 9 were more potent than those of the reference compound sodium cromoglycate at the same concentrations. The biochemical results were consistent with the morphological findings obtained by light and transmission electron microscopy. This study reports, for the first time, that the new synthetic compounds methyl (Z)- 2-bromo-3-(furan-3-yl)acrylate (compound 5) and methyl (E)- 2-bromo-3-(3-bromophenyl)acrylate (compound 9) strongly inhibit mast cell degranulation, without affecting cell viability. The implications of these results are relevant as a basis for developing new anti-inflammatory and mast cell stabilizing drugs.
Collapse
Affiliation(s)
- Maricel Martínez
- Instituto de Histología y Embriología "Dr. Mario H. Burgos" (IHEM, UNCUYO-CONICET), Universidad Nacional de Cuyo, Mendoza, Argentina; Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina; Instituto de Investigaciones en Tecnología Química (INTEQUI-CONICET), Universidad Nacional de San Luis, San Luis, Argentina
| | - María Laura Mariani
- Instituto de Histología y Embriología "Dr. Mario H. Burgos" (IHEM, UNCUYO-CONICET), Universidad Nacional de Cuyo, Mendoza, Argentina; Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina
| | - Celina García
- Instituto Universitario de Bio-Organica "Antonio Gonzalez", Universidad de La Laguna, La Laguna, Tenerife, Spain
| | - Juan Pedro Ceñal
- Instituto de Investigaciones en Tecnología Química (INTEQUI-CONICET), Universidad Nacional de San Luis, San Luis, Argentina; Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, San Luis, Argentina
| | - Alicia Beatriz Penissi
- Instituto de Histología y Embriología "Dr. Mario H. Burgos" (IHEM, UNCUYO-CONICET), Universidad Nacional de Cuyo, Mendoza, Argentina; Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina.
| |
Collapse
|
2
|
Xie Y, Liu Y, Sun J, Zheng L. Synthesis of mitochondria-targeted ferulic acid amide derivatives with antioxidant, anti-inflammatory activities and inducing mitophagy. Bioorg Chem 2022; 127:106037. [PMID: 35863132 DOI: 10.1016/j.bioorg.2022.106037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 07/12/2022] [Accepted: 07/14/2022] [Indexed: 11/18/2022]
Abstract
The seventeen ferulic acid amide derivatives were synthesized by coupling mitochondrial carrier coumarin-3-carboxamide with acrylic acids. The results of cellular antioxidant activity and inhibitory effects on NO production against LPS-stimulated RAW264.7 macrophages indicated four compounds (8c, 8d, 9c, 9d) showed the higher dual-activities of antioxidant and anti-inflammatory. The structure-activity relationship was deduced. In regard to mechanism research, the most potent compound 8d which mainly distributed in mitochondria suppressed the secretion of inflammatory cytokines IL-6 and TNF-α, enhancing mitophagy to alleviate inflammatory response. Besides, the dual-activities were diminished by removal of coumarin carrier in 8d, suggesting the enrichment in mitochondria might be important for activities. This study showed that development of mitochondria-targeted antioxidants could be a feasible strategy to resist inflammation.
Collapse
Affiliation(s)
- Yu Xie
- School of Pharmacy, Lanzhou University, Lanzhou 730000, China
| | - Yongpeng Liu
- School of Pharmacy, Lanzhou University, Lanzhou 730000, China
| | - Jing Sun
- School of Pharmacy, Lanzhou University, Lanzhou 730000, China
| | - Lifang Zheng
- School of Pharmacy, Lanzhou University, Lanzhou 730000, China.
| |
Collapse
|
3
|
Gu X, Li X, Guan M, Jiang C, Song Q, Sun N, Zou Y, Zhou Q, Chen J, Qiu J. Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells. Bioorg Med Chem Lett 2020; 30:127638. [PMID: 33132117 DOI: 10.1016/j.bmcl.2020.127638] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 10/02/2020] [Accepted: 10/18/2020] [Indexed: 01/30/2023]
Abstract
P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a major obstacle to successful chemotherapy for leukemia. In this study, a series of thiosemicarbazone-containing compounds (4a-b, 7a-q) were synthesized. Biological evaluation showed that the most active compound 7e displayed potent anti-leukemia activity against P-gp overexpressing drug-resistant K562/A02 cells, with an IC50 value of 0.44 μM. Notably, compound 7e exhibited a selective killing effect on K562/A02 cells by dose-dependently increasing the intracellular levels of reactive oxygen species (ROS), thus exerting a potential collateral sensitivity (CS)-promoting effect in vitro. Moreover, compound 7e could inhibit HDAC1 and HDAC6, and induce the apoptosis of K562/A02 cells by increasing the expression of Bax, decreasing Bcl-2 protein level, and promoting the cleavage of caspase-3 and PARP, respectively. Overall, 7e may be a potential anti-cancer agent against drug-resistant myelogenous leukemia.
Collapse
Affiliation(s)
- Xiaoke Gu
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China.
| | - Xin Li
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China
| | - Mingyu Guan
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China
| | - Chunyu Jiang
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China
| | - Qinghua Song
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China
| | - Nan Sun
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China
| | - Yueting Zou
- Department of Pharmaceutical Analysis, School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China
| | - Qingqing Zhou
- Department of Pharmaceutical Analysis, School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China
| | - Jing Chen
- Department of Pharmaceutical Analysis, School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China
| | - Jingying Qiu
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China; Department of Pharmaceutical Analysis, School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, People's Republic of China.
| |
Collapse
|
4
|
Moos WH, Faller DV, Glavas IP, Harpp DN, Kanara I, Pinkert CA, Powers WR, Sampani K, Steliou K, Vavvas DG, Kodukula K, Zamboni RJ. Epigenetic treatment of dermatologic disorders. Drug Dev Res 2019. [DOI: 10.1002/ddr.21562] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Walter H. Moos
- Department of Pharmaceutical Chemistry, School of PharmacyUniversity of California, San Francisco San Francisco California
- ShangPharma Innovation Inc. South San Francisco California
| | - Douglas V. Faller
- Department of MedicineBoston University School of Medicine Boston Massachusetts
- Cancer Research CenterBoston University School of Medicine Boston Massachusetts
| | - Ioannis P. Glavas
- Department of OphthalmologyNew York University School of Medicine New York City New York
| | - David N. Harpp
- Department of ChemistryMcGill University Montreal Quebec Canada
| | | | - Carl A. Pinkert
- Department of Pathobiology, College of Veterinary MedicineAuburn University Auburn Alabama
| | - Whitney R. Powers
- Department of Health SciencesBoston University Boston Massachusetts
- Department of AnatomyBoston University School of Medicine Boston Massachusetts
| | - Konstantina Sampani
- Beetham Eye InstituteJoslin Diabetes Center Boston Massachusetts
- Department of MedicineHarvard Medical School Boston Massachusetts
| | - Kosta Steliou
- Cancer Research CenterBoston University School of Medicine Boston Massachusetts
- PhenoMatriX, Inc. Natick Massachusetts
| | - Demetrios G. Vavvas
- Retina Service, Angiogenesis LaboratoryMassachusetts Eye and Ear Infirmary Boston Massachusetts
- Department of OphthalmologyHarvard Medical School Boston Massachusetts
| | - Krishna Kodukula
- ShangPharma Innovation Inc. South San Francisco California
- PhenoMatriX, Inc. Natick Massachusetts
| | | |
Collapse
|
5
|
Chen YJ, Tang ZZ, Du L, Liu Y, Lu Q, Ma TF, Liu YW. A novel compound AB-38b improves diabetes-associated cognitive decline in mice via activation of Nrf2/ARE pathway. Brain Res Bull 2019; 150:160-167. [DOI: 10.1016/j.brainresbull.2019.05.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 04/30/2019] [Accepted: 05/14/2019] [Indexed: 12/14/2022]
|
6
|
Gu X, Chen J, Zhang Y, Guan M, Li X, Zhou Q, Song Q, Qiu J. Synthesis and assessment of phenylacrylamide derivatives as potential anti-oxidant and anti-inflammatory agents. Eur J Med Chem 2019; 180:62-71. [PMID: 31301564 DOI: 10.1016/j.ejmech.2019.07.020] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2019] [Revised: 07/04/2019] [Accepted: 07/06/2019] [Indexed: 12/11/2022]
Abstract
Oxidative stress and inflammation are major causes of numerous life-threatening human diseases. In the present study, we synthesized a series of phenylacrylamide derivatives as novel anti-oxidant and anti-inflammatory agents. Biological evaluation showed that compound 6a could more potently protect HBZY-1 mesangial cells from H2O2-caused oxidative stress than positive controls resveratrol and sulforaphane by dose- and time-dependently impairing the ROS accumulation. Preliminary anti-oxidant mechanism studies indicated that compound 6a could activate Nrf2 and increase the protein and mRNA expression of downstream anti-oxidant enzymes, ie. NQO-1, HO-1, GCLM and GCLC. Notably, 6a could inhibit the production of NO and the activity of NF-κB in LPS-stimulated HBZY-1 mesangial cells, indicating its potential anti-inflammatory activity. Interestingly, both effects could be significantly attenuated by Nrf2 inhibitor TRG, HO-1 inhibitor ZnPP or GCL inhibitor BSO at non-toxic concentrations, confirming that the anti-oxidant and anti-inflammatory activity of 6a is related to the activation of Nrf2 signaling pathway. These results, together with the relatively safety profile, indicated that compound 6a could be a promising lead to develop novel anti-oxidant and anti-inflammatory agents, thus preventing diseases induced by oxidative stress and inflammation.
Collapse
Affiliation(s)
- Xiaoke Gu
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China.
| | - Jing Chen
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Yinpeng Zhang
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Mingyu Guan
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Xin Li
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Qingqing Zhou
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Qinghua Song
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Jingying Qiu
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China.
| |
Collapse
|